Maegim한국어

티앤엘

340570KOSDAQSector: Pharma & Biotech
₩52,800▲ 4.97%Market cap ₩429.2BAs of Jul 21, 2026 close · updated once daily
A
Grade A71.8 ptsTop 8% of 2,523 stocks
Financial strength
91.0
Growth momentum
55.9
Price attractiveness
61.2

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

91.0
How much debt does it carry relative to equity?
Debt-to-equity ratio
7.9%
✓ Above median · Top 8.3% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
830.2%
✓ Above median · Top 18.5% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
28.2%
✓ Above median · Top 4.7% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
18.9%
✓ Above median · Top 4.7% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

55.9
How much did revenue grow in a year?
Revenue growth (YoY)
-6.1%
✗ Below median · Top 75.6% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
26.2%
✓ Above median · Top 10.2% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-18.6%
✗ Below median · Top 71.2% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
90.7%
✓ Above median · Top 19.6% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

61.2
Is the price expensive relative to earnings?
P/E (price-to-earnings)
11.3x
✓ Above median · Top 17.3% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
2.13x
✗ Below median · Top 60.4% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15